Discovery research

Milosevich SAF, Boyd, DB. Supercomputing and drug discovery research. Per-spect Drug Discovery Design 1993 1 345-58. 

Uncertainty from the viewpoint of the discovery researcher consists both of controllable and uncontrollable risks [23],... 

Jang GR, Harris RZ, Lau DT. Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev 2001 21 382-96. 

The popular permeability equations [(7.10) and (7.11)] derived in the preceding section presume that the solute does not distribute into the membrane to any appreciable extent. This assumption may not be valid in drug discovery research, since most of the compounds synthesized by combinatorial methods are very lipophilic and can substantially accumulate in the membrane. Neglecting this leads to underestimates of permeability coefficients. This section expands the equations to include membrane retention. 

This work was supported through the NSERC Discovery research program. 

Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA... 

Discovery research, on macrolide antibiotics, 15 305-306 Discrete optimization problems,... 

Preclinical studies Animal studies that support Phase I safety and tolerance studies and must comply with Good Laboratory Practice (GLP). Other preclinical studies are done in discovery research laboratories to support drug efficiency claims. 

Jean-Marc Sabatier has a Ph.D. and HDR in biochemistry. He is the director of research at the French Centre National de la Recherche Scientifique (CNRS). He heads a research laboratory (ERT 62) entided Engineering of Therapeutic Peptides at the Universite de la Mediterranee, in Marseilles, France. He also holds the position of a senior director (discovery research — peptides) for a public company in Canada. Dr. Sabatier works in the field of animal toxins, and leads the venom peptide group of the International Neuropeptide Society. He also designs immunomodulatory and antiviral drugs, as well as contributes to the field of peptide and protein engineering. He has contributed more than 100 scientific articles, 180 communications, and 43 patents. He is a member of several scientific advisory boards of journals (e.g.. Peptides, Biochemical Journal), and has reviewed articles submitted for publication in more than 30 specialized international journals. 

---